Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention

Trial ID or NCT#

NCT00285857

Status

not recruiting iconNOT RECRUITING

Purpose

The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.

Official Title

A Phase 2 Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer

Eligibility Criteria

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Allison W. Kurian, M.D., M.Sc.
Allison W. Kurian, M.D., M.Sc.
Medical oncologist, Breast specialist, Cancer geneticist
Professor of Medicine (Oncology) and of Epidemiology and Population Health

Contact us to find out if this trial is right for you.

Contact

Meredith Mills
6507245223

View on ClinicalTrials.gov